* 中国生物科技公司--康方生物9926.HK周五早盘高开5%，随后涨幅扩大至5.5%，续创2020年上市以来新高。
* 该公司此前公告称，派安普利已获得美国食品药品监督管理局（FDA）批准上市，用于治疗复发或转移性鼻咽癌的一线治疗和以铂类为基础的至少一线化疗治疗失败后治疗的2项适应症，是公司第一个获得美国FDA批准上市的自主研发创新生物药。
* 康方生物今年迄今劲涨67.9%，同期恒生指数.HSI上扬9.9%。
* 恒生香港上市生物科技指数.HSHKBIO盘中一度升2%。（完）
更多股市简讯请点选CN-CMN-HOT
(发稿 徐凯文；审校 张喜良)
((kaiwen.xu@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.